These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33825507)

  • 21. Ivacaftor for the treatment of cystic fibrosis in children under six years of age.
    Aoyama BC; Mogayzel PJ
    Expert Rev Respir Med; 2020 Jun; 14(6):547-557. PubMed ID: 32154747
    [No Abstract]   [Full Text] [Related]  

  • 22. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
    Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
    Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis.
    Harwood KH; McQuade RM; Jarnicki A; Schneider-Futschik EK
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
    Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
    Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.
    Bernarde C; Keravec M; Mounier J; Gouriou S; Rault G; Férec C; Barbier G; Héry-Arnaud G
    PLoS One; 2015; 10(4):e0124124. PubMed ID: 25853698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
    Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
    Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potentiation of the cystic fibrosis transmembrane conductance regulator Cl
    Wang Y; Cai Z; Gosling M; Sheppard DN
    Am J Physiol Lung Cell Mol Physiol; 2018 Nov; 315(5):L846-L857. PubMed ID: 30136610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
    Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN
    Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR.
    Eastman AC; Pace RG; Dang H; Aksit MA; Vecchio-Pagán B; Lam AN; O'Neal WK; Blackman SM; Knowles MR; Cutting GR
    J Cyst Fibros; 2021 Sep; 20(5):851-856. PubMed ID: 33674211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics.
    Kunzelmann K; Mall M
    Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical reversal of chronic sinusitis in a cystic fibrosis patient with ivacaftor.
    Chang EH; Tang XX; Shah VS; Launspach JL; Ernst SE; Hilkin B; Karp PH; Abou Alaiwa MH; Graham SM; Hornick DB; Welsh MJ; Stoltz DA; Zabner J
    Int Forum Allergy Rhinol; 2015 Feb; 5(2):178-81. PubMed ID: 25363320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy.
    Birket SE; Chu KK; Houser GH; Liu L; Fernandez CM; Solomon GM; Lin V; Shastry S; Mazur M; Sloane PA; Hanes J; Grizzle WE; Sorscher EJ; Tearney GJ; Rowe SM
    Am J Physiol Lung Cell Mol Physiol; 2016 May; 310(10):L928-39. PubMed ID: 26968770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis.
    Putman MS; Greenblatt LB; Bruce M; Joseph T; Lee H; Sawicki G; Uluer A; Sicilian L; Neuringer I; Gordon CM; Bouxsein ML; Finkelstein JS
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1248-e1261. PubMed ID: 33258950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
    Ramsey BW; Davies J; McElvaney NG; Tullis E; Bell SC; Dřevínek P; Griese M; McKone EF; Wainwright CE; Konstan MW; Moss R; Ratjen F; Sermet-Gaudelus I; Rowe SM; Dong Q; Rodriguez S; Yen K; Ordoñez C; Elborn JS;
    N Engl J Med; 2011 Nov; 365(18):1663-72. PubMed ID: 22047557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR.
    Donaldson SH; Laube BL; Corcoran TE; Bhambhvani P; Zeman K; Ceppe A; Zeitlin PL; Mogayzel PJ; Boyle M; Locke LW; Myerburg MM; Pilewski JM; Flanagan B; Rowe SM; Bennett WD
    JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients.
    McCormick J; Cho DY; Lampkin B; Richman J; Hathorne H; Rowe SM; Woodworth BA
    Int Forum Allergy Rhinol; 2019 Mar; 9(3):292-297. PubMed ID: 30472785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ivacaftor potentiation of multiple CFTR channels with gating mutations.
    Yu H; Burton B; Huang CJ; Worley J; Cao D; Johnson JP; Urrutia A; Joubran J; Seepersaud S; Sussky K; Hoffman BJ; Van Goor F
    J Cyst Fibros; 2012 May; 11(3):237-45. PubMed ID: 22293084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.